| Autor: |
Wick M; Evidence-based Medicine / Health Economics & Outcomes Research, Sanofi-Aventis Deutschland GmbH, Berlin, Germany., Kliemt R; Health Services Research and Health Economics, WIG2 GmbH, Leipzig, Germany., Poshtiban A; Evidence-based Medicine / Health Economics & Outcomes Research, Sanofi-Aventis Deutschland GmbH, Berlin, Germany., Kossack N; Health Services Research and Health Economics, WIG2 GmbH, Leipzig, Germany., Diller GP; Adult Congenital and Valvular Heart Disease Center, Department of Cardiology and Angiology, University Hospital Muenster, Muenster, Germany.; Competence Network for Congenital Heart Defects, Deutsches Herzzentrum Berlin, Berlin, Germany., Soudani S; Health Economics & Value Assessment Vaccines, Sanofi Vaccines, Lyon, France., Bangert M; Health Economics & Value Assessment Vaccines, Sanofi Vaccines, Lyon, France., Kramer R; Health Economics & Value Assessment Vaccines, Sanofi Vaccines, Lyon, France., Damm O; Evidence-based Medicine / Health Economics & Outcomes Research, Sanofi-Aventis Deutschland GmbH, Berlin, Germany. |
| Abstrakt: |
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children worldwide. Using routine statutory health insurance claims data including patients from all regions of Germany, we investigated the health-care resource use and costs associated with RSV prophylaxis with palivizumab in Germany. In the database, infants from the birth cohorts 2015-2019 eligible for palivizumab immunization were identified using codes of the 10 th revision of the International Classification of Diseases (ICD-10). Health-care resource use and costs related to immunization were determined by inpatient and outpatient administrations. Over the study period, only 1.3% of infants received at least one dose of palivizumab in their first year of life. The mean number of doses per immunized infant was 4.6. From a third-party payer perspective, the mean costs of palivizumab per infant who received at least one dose in the first year of life was €5,435 in the birth cohorts 2015-2019. Despite the substantial risk of severe RSV infection, we found low rates of palivizumab utilization. Novel preventive interventions, featuring broader indications and single-dose administration per season, contribute to mitigating the burden of RSV disease across a more extensive infant population. |
